



महामना पंडित मदन मोहन मालवीय कैंसर केंद्र एवं होमी भाभा कैंसर अस्पताल  
MAHAMANA PANDIT MADAN MOHAN MALAVIYA CANCER CENTRE  
& HOMI BHABHA CANCER HOSPITAL

(टाटा स्मारक केंद्र की इकाईयां / Units of TATA MEMORIAL CENTRE)  
परमाणु ऊर्जा विभाग, भारत सरकार / DEPT. OF ATOMIC ENERGY, GOVT. OF INDIA  
वाराणसी, उत्तर प्रदेश - 221005 / VARANASI, UTTAR PRADESH - 221005



Advt. No. HBCH/MPMCC/PROJECT/2025/27

Date: 18.06.2025

## WALK-IN INTERVIEW

Reporting time: 09:00 A.M. to 10:00 A.M.  
(Project based vacancies)

Eligible and interested candidates are invited to attend the Walk-In Interview at Mahamana Pandit Madan Mohan Malviya Cancer Centre, Sunder Bagiya, B.H.U Campus, Varanasi, Uttar Pradesh – 221005. Candidates must bring Bio-data (Resume), Recent passport size photograph, PAN card, Aadhar card, Educational Certificates, Experience certificates in original and one set of self-attested copies, on the interview date(s).

(1)	<b>Name of Post</b>	<b>Clinical Trial Coordinator</b>
	<b>No. of Vacancy</b>	<b>07 (seven)</b>
	<b>Walk-In Interview Date</b>	<b>Saturday, 21.06.2025</b>
	<b>Monthly Remuneration:</b>	Rs. 25,000/- to Rs. 35,000/-
	<b>Eligibility Criteria</b>	Graduate degree in science with PG Diploma in Clinical Research.  Experience of one year in relevant filed is desirable.
	<b>Project Name &amp; A/c No.</b>	(i) IM Project-TRAC (Project A/c 9221) (01-Post) (ii) A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. (Project A/c 9490) (01-Post) (iii) PACIFIC-08: A phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose disease has not progressed following definitive Platinum-based Concurrent Chemo radiation Therapy. (Project A/c No. 160009) (01-Post) (iv) Study Code D9673L00012: A Prospective, Multi-Center, Phase 4, Single Arm Study to assess the safety of Transtuzumab Deruxtecan, an Anti-her2-antibody drug conjugate in Indian patients with unresectable or metastatic her2-based regimen. (Project A/c No. 180003) (01-Post) (v) A randomized, double blind, parallel-group study to Compare efficacy, safety, and immunogenicity of GME751 (proposed pembrolizumab biosimilar) and EU-authorized Keytruda® in adult participants with untreated metastatic non-squamous non-small cell lung cancer (NSCLC). (Project A/c No. 160011) (01-Post) (vi) SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression. (Project A/c No. 160025) (01-Post) (vii) A Phase Ib/III, Open-label, Randomised Study of Capiwasertib plus CKD4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) (Project A/c No. 9256) (01-Post)
(2)	<b>Name of Post</b>	<b>Junior Research Fellow (Non-Medical)</b>
	<b>No. of Vacancy</b>	<b>01 (one)</b>
	<b>Walk-In Interview Date</b>	<b>Monday, 23.06.2025</b>
	<b>Monthly Remuneration:</b>	Rs. 40,000/- to Rs. 45,000/-
	<b>Eligibility Criteria</b>	Post-Graduation in life science.
	<b>Project Name &amp; A/c No.</b>	Palliative Triple Oral Metronomic Therapy and Low-Dose Nivolumab with or without Hypo fractionated Radiotherapy: A randomized Phase III Trial (PALLADIUM Trial) (Project A/c No. 160039)
(3)	<b>Name of Post</b>	<b>Clinical Psychologist</b>
	<b>No. of Vacancy</b>	<b>01 (one)</b>
	<b>Walk-In Interview Date</b>	<b>Monday, 23.06.2025</b>
	<b>Monthly Remuneration:</b>	Rs. 25,000/- to Rs. 42,000/-
	<b>Eligibility Criteria</b>	M.A / M. Phill. In Clinical Psychology / General Psychology with minimum 01-year clinical experience.  Any Fellowship in Clinical Psychology / Ph.D. is desirable.
	<b>Project Name &amp; A/c No.</b>	Integrated Comprehensive Palliative Care (Project A/c No. 9455)



महामना पंडित मदन मोहन मालवीय कैंसर केंद्र एवं होमी भाभा कैंसर अस्पताल  
MAHAMANA PANDIT MADAN MOHAN MALAVIYA CANCER CENTRE  
& HOMI BHABHA CANCER HOSPITAL

(टाटा स्मारक केंद्र की इकाईयां / Units of TATA MEMORIAL CENTRE)  
परमाणु ऊर्जा विभाग, भारत सरकार / DEPT. OF ATOMIC ENERGY, GOVT. OF INDIA  
वाराणसी, उत्तर प्रदेश - २२१००५ / VARANASI, UTTAR PRADESH - 221005



(4)	<b>Name of Post</b>	Research Assistant
	<b>No. of Vacancy</b>	01 (one)
	<b>Walk-In Interview Date</b>	Wednesday, 25.06.2025
	<b>Monthly Remuneration:</b>	Rs. 23,000/-
	<b>Eligibility Criteria</b>	Graduate degree in science.
<b>Project Name &amp; A/c No.</b>		Academic Fund (Project A/c No. 9299)

(5)	<b>Name of Post</b>	Data Entry Operator
	<b>No. of Vacancy</b>	01 (one)
	<b>Walk-In Interview Date</b>	Wednesday, 25.06.2025
	<b>Monthly Remuneration:</b>	Rs. 21,100/-
	<b>Eligibility Criteria</b>	Graduate degree with a minimum six-month computer course from a recognized institute.
<b>Project Name &amp; A/c No.</b>		Academic Fund (Project A/c No. 9299)

**Note:**

1. The tenure will be valid for six months and may be extended further based on satisfactory performance and the institute's requirement.
2. If there are many applicants, an MCQ test will be conducted as a shortlisting criterion, and only eligible candidates will be invited for the interview accordingly.
3. Outstation candidates are advised that accommodation will not be provided.

(Piyush Tripathi)  
Administrative Officer III (HRD)